NCT05852730View on ClinicalTrials.gov

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 10, 2021

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Motion Sickness, SpaceMotion SimulationParabolic Flight
Interventions
DRUG

DPI-386 Nasal Gel

Subjects will self-administer DPI-386 Nasal Gel

DRUG

Other (e.g., promethazine, meclizine)

Subjects will self-administer other medications as available.

Trial Locations (1)

77058

RECRUITING

NASA Johnson Space Center Neuroscience Laboratory, Houston

All Listed Sponsors
collaborator

National Aeronautics and Space Administration (NASA)

FED

lead

Repurposed Therapeutics, Inc.

INDUSTRY